Fintel reports that on November 4, 2025, Citizens maintained coverage of Benitec Biopharma (NasdaqCM:BNTC) with a Market ...

H.C. Wainwright raised the firm’s price target on Benitec Biopharma (BNTC) to $35 from $28 and keeps a Buy rating on the shares. The company ...

Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

The FDA’s Fast Track designation follows the agency’s review of the interim data. BB-301 has also previously received Orphan Drug Designation from both the FDA and European Medical Association.

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...

This year has brought a range of challenges for biopharma companies and their leaders, including on-and-off tariff threats and President Donald Trump's arm-twisting around overseas drug spending. Now, ...

Merck headquarters in Rahway, NJ. RAHWAY, N.J.- Merck has completed its $10 billion buyout of the British biopharmaceutical company Verona. The deal was first announced in July. It brings the chronic ...

This story was updated at 3:30 p.m. Monday, Oct. 6 to include more information from Takeda. A major pharmaceutical company will be laying off more than 100 people at multiple Cambridge locations next ...

Sutro Biopharma was once worth $1 billion, another Bay Area biotech company with deep coffers and a novel research plan. And now, like at so many of its peers, the layoffs are stacking up. After ...